Advances in immunotherapy of hematologic malignancies

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 237-243

  Maloney, David G ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BISMUTH; BUSULFAN; CALICHEAMICIN; CANCER ANTIBODY; CD20 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG CONJUGATION; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SUICIDE GENE; VACCINATION;

EID: 0032413976     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00002     Document Type: Review

References (40)

1. Brown SL, Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989, 73:651-661.
2. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996, 88:637a.
3. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
4. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457-2466.
5. Maloney DG, Grillolopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al.: Idec-C2b8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkins lymphoma. J Clin Oncol 1997, 15:3266-3274.
6. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart •• JA, et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195. This article describes the treatment of 37 patients using rituxan at 375 mg/m2. Thirty-four of these patients had low-grade or follicular NHL, and there was a 50% response rate, with a 10.4 months median-duration time to progression. Minimal infusional symptoms were noted. Peripheral blood B cells were depleted, but there was no increase in infections. Patients with a follicular histology had a higher response rate. Responses were observed even in patients with bulky disease.
7. McLaughlin P, Cabanillas F, Grillo-Lopez AJ, Link BK, Levy R, Czuczman M, et al.: IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 1996, 88:90a.
8. Czuzman MS, Grillo-Lopez AJ, Saleh M, Gordon L, Jonas C, White CA, et al.: IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: interim clinical and bcl-2 (PCR) results. Ann Oncol 1996, 7(Suppl 1):56.
9. Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A: Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996, 98:2819-2826.
10. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-• Nelemans JC, Fibbe WE, Willemze R, Catovsky D: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997, 15:2667-2672. Although a rare disease, this illustrates the activity of Campath-1H mAb. Overall, 11 of 15 patients responded to the mAb and nine had a CR. Complications included marrow aplasia in two patients. However, this is a dramatic effect in patients with a usually rapidly fatal disease. Two patients went on to successful autografts while in remission using stem cells collected during first CR.
11. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, •• Mellstedt H: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574. The response rate in previously treated chronic lymphocytic leukemia was 42%, however 28 of 29 patients cleared the peripheral blood of chronic lymphocytic leukemia cells, but only 36% cleared the bone marrow. Minimal effects were observed in lymph nodes. First infusion symptoms were moderate and six patients developed serious infections from the resulting immunodeficiency.
12. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H: Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996, 93:151-153.
13. Caron PC, Jurcic JG, Dumont L, Tyson D, Scheinberg DA: High-dose infusional humanized anti-CD33 M195: prospects for treating minimal disease in myeloid leukemia. Blood 1996, 88:218a.
14. Jurcic JG, DeBlasio A, Dumont L, Warrell RP, Scheinberg DA: Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Blood 1997, 90:416a.
15. Caspar CB, Levy S, Levy R: Idiotype vaccines for non-Hodgkins lymphoma • induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997, 90:3699-3706. The Stanford group demonstrates that vaccination with an idiotype from a human tumor in mice using a variety of methods can elicit an immune response that can cover the idiotype negative variants that arose in that patient following treatment with an anti-idiotype mAb. This suggests that idiotype variants should be less of an issue in the idiotype vaccine trial than had been observed previously in the therapy trials with anti-idiotype mAbs. This is likely because of the induction of a polyclonal immune response.
16. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, •• Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135. This is an excellent follow up of the idiotype vaccination trial at Stanford. Immune responses were observed in 49% of patients. Patients in CR with an immune response had longer disease-free and overall survival compared to patients in CR who did not make an immune response to the vaccine. Responses to the carrier protein KLH were similar in both groups.
17. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020.
18. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, • Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996, 14:1974-1981. This is a good review of the field of radioimmunotherapy, especially of an update of the high-dose 1311-B1 transplantation trials of the Seattle group. Follow-up of the phase I and II clinical trials is provided.
19. Kaminski MS, Vose J, Saleh M, Lister A, Knox S, Crowther D, et al.: A multicenter phase II study of iodine-131 anti-B1 antibody (Bexxar) in patients with chemotherapy-relapsed/refractory low-grad or transformed low grade B cell non-Hodgkin's lymphoma [abstract]. Blood 1997, 90:509a.
20. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, et al.: Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma. Clinical Cancer Research 1996, 2:457-470.
21. Witzig T, Wiseman G, White CA, Solinger A, Gordon L, Raubitschek A, et al: IDEC-Y2B8 90ytrrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma: interim results of a phase I/II trial [abstract]. Blood 1997, 90:586a.
22. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224.
23. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al.: Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995, 346:336-340.
24. 131I-B1 transplant trials of the Seattle group. Follow-up of the phase I and II clinical trials is provided.
25. Matthews DC, Appelbaum FR, Eary JF, Mitchell D, Press OW, Bernstein ID: 1311-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission [abstract]. Blood 1996, 88:142a.
26. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, et al.: Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995, 85:1122-1131.
27. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blattler WA: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992, 79:576-585.
28. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, et al.: A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996, 88:1188-1197.
29. Sievers EL, Appelbaum FA, Spielberger RT, Forman SJ, Flowers DA, Berger MS, Shannon-Dorcy K, Bernstein ID: Selective ablation of acute myeloid leukemia using an anti-CD33 chlicheamicin immunoconjugate. Blood 1997, 90:504a.
30. LeMaistre CF, Saleh MN, Kuzel TM, Foss F, Platanias LC, Schwartz G, •• Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Nichols JC: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998, 91:399-405. This is a large trial of the DAB389IL-2 fusion toxin in patients with CD25 positive malignancies. Activity was observed in patients with cutaneous T-cell lymphoma (13 of 35), NHL (3 of 17), but no responses were observed in 21 patients with Hodgkin's disease.
31. Kuzel T, Olsen E, Martin A, Kim Y, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of DAB 389IL-2 (Ontaka) for the treatment of mycosis fungoides. Blood 1997, 90:586a.
32. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF: • Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211. This article describes donor lymphocyte infusions in 13 patients with relapsed myeloma following allografting. Eight of 13 patients responded, and seven of these developed acute graft-versus-host disease. Higher T-cell doses induced greater graft-versus-host disease and a higher response rate. (See Bonini et al., Science 1997, 276:1719-1724 for a means to control graft-versus-host disease).
33. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF: • Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997, 90:4206-4211. This article describes donor lymphocyte infusions in 13 patients with relapsed myeloma following allografting. Eight of 13 patients responded, and seven of these developed acute graft-versus-host disease. Higher T-cell doses induced greater graft-versus-host disease and a higher response rate. (See Bonini et al., Science 1997, 276:1719-1724 for a means to control graft-versus-host disease).
34. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, •• Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276:1719-1724. This is an important article demonstrating that donor lymphocyte infusions can cure relapsed leukemia and Epstein-Barr virus-induced lymphomas that arose after T-cell depleted bone marrow transplantation. A complication of donor lymphocyte infusion is the induction of graft-versus-host disease. The donor cells were transduced with a suicide gene and could then be eliminated by the administration of ganciclovir following the successful elimination of the disease. The serious complications of graft-versus-host disease (which also provide the antitumor effect) thus could be controlled.
35. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
36. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, Lupton SD, Overell RW, Reynolds TC, Corey L, Greenberg PD: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Medicine 1996, 2:216-223.
37. Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD: Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol 1996, 157:4079-4086.
38. Yee C, Riddell SR, Greenberg PD: Prospects for adoptive T cell therapy. Curr Opin Immunol 1997, 9:702-708.
39. Schultze JL, Seamon MJ, Michalak S, Gribben JG, Nadler LM: Autologous • tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997, 89:3806-3816. T cells isolated from follicular NHL lymph node biopsies can be stimulated to proliferate when stimulated with autologous tumor cells that had been activated through CD40 and with interleukin-2. These T cells can lyse the tumor cells, but the targets have not yet been defined. Cloning of these T cells and evaluation of the antigens recognized may provide a powerful new treatment for follicular NHL patients.
40. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E. Greenberg PD: Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV + Hodgkin's disease. Blood 1997, 89:1978-1986.